These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 7488445)
21. Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients? Brügemann J; de Graeff PA; van der Meer J; Lie KI Drugs Aging; 1995 Aug; 7(2):110-6. PubMed ID: 7579782 [TBL] [Abstract][Full Text] [Related]
22. Fibrinolytic treatment in suspected acute myocardial infarction--use and risks in clinical practice. Beermann B; von Bahr C; Sundström A Eur J Clin Pharmacol; 1997; 52(3):179-82. PubMed ID: 9218923 [TBL] [Abstract][Full Text] [Related]
23. Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits? Gurewich V; Muller J Am J Cardiol; 1996 Apr; 77(9):756-8. PubMed ID: 8651129 [No Abstract] [Full Text] [Related]
24. Can anti-streptokinase antibody predict myocardial infarction outcomes after streptokinase treatment? Sadeghi M; Golabchi A; Haghani P; Gharipour M; Naderi GA; Sarrafzadegan N J Pak Med Assoc; 2012 Mar; 62(3 Suppl 2):S31-4. PubMed ID: 22768454 [TBL] [Abstract][Full Text] [Related]
25. Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Gemmill JD; Hogg KJ; Dunn FG; Rae AP; Hillis WS Br Heart J; 1994 Sep; 72(3):222-5. PubMed ID: 7946770 [TBL] [Abstract][Full Text] [Related]
26. Thrombolytic failure with streptokinase in acute myocardial infarction using electrocardiogram criteria. Lee YY; Tee MH; Zurkurnai Y; Than W; Sapawi M; Suhairi I Singapore Med J; 2008 Apr; 49(4):304-10. PubMed ID: 18418522 [TBL] [Abstract][Full Text] [Related]
27. Clot-busting drugs linked to increased mortality in the very elderly. Levenson D Rep Med Guidel Outcomes Res; 2002 Apr; 13(7):1-2, 5. PubMed ID: 12452167 [No Abstract] [Full Text] [Related]
28. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. Özkan M; Gündüz S; Biteker M; Astarcioglu MA; Çevik C; Kaynak E; Yıldız M; Oğuz E; Aykan AÇ; Ertürk E; Karavelioğlu Y; Gökdeniz T; Kaya H; Gürsoy OM; Çakal B; Karakoyun S; Duran N; Özdemir N JACC Cardiovasc Imaging; 2013 Feb; 6(2):206-16. PubMed ID: 23489534 [TBL] [Abstract][Full Text] [Related]
29. Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. The European Secondary Prevention Study Group. Ketley D; Woods KL Br Heart J; 1995 Sep; 74(3):224-8. PubMed ID: 7547014 [TBL] [Abstract][Full Text] [Related]
30. Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase. Smith BJ J Accid Emerg Med; 1999 Nov; 16(6):407-11. PubMed ID: 10572811 [TBL] [Abstract][Full Text] [Related]
31. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. GUSTO investigators N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123 [TBL] [Abstract][Full Text] [Related]
33. Coronary care follow-up study: acute care required immediately following thrombolytic therapy. Ellicott C; Shaw DB; Kirby BJ; Bailey T J R Soc Med; 1993 Jun; 86(6):324-7. PubMed ID: 8315624 [TBL] [Abstract][Full Text] [Related]
34. Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial. Özkan M; Kalçık M; Gürsoy MO; Öcal L; Griffini S; Karakoyun S; Yesin M; Gündüz S; Astarcıoğlu MA; Bayam E; Cerşit S; Aykan AÇ; Cugno M J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):372-80. PubMed ID: 26657322 [TBL] [Abstract][Full Text] [Related]
35. Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy. Naylor CD; Armstrong PW CMAJ; 1989 Jun; 140(11):1289-99. PubMed ID: 2497946 [TBL] [Abstract][Full Text] [Related]
36. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. Maggioni AP; Franzosi MG; Santoro E; White H; Van de Werf F; Tognoni G N Engl J Med; 1992 Jul; 327(1):1-6. PubMed ID: 1598096 [TBL] [Abstract][Full Text] [Related]
37. Efficacy of a new accelerated streptokinase regime in acute myocardial infarction: a double blind randomized clinical trial. Ghaffari S; Kazemi B; Golzari IG Cardiovasc Ther; 2013 Feb; 31(1):53-9. PubMed ID: 21884018 [TBL] [Abstract][Full Text] [Related]
39. Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction. McLeod DC; Coln WG; Thayer CF; Perfetto EM; Hartzema AG Ann Pharmacother; 1993; 27(7-8):956-62. PubMed ID: 8364282 [TBL] [Abstract][Full Text] [Related]
40. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC). Johnson ES; Cregeen RJ Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]